Corcept Therapeutics Incorporated (CORT): insider & executive buying
Corcept Therapeutics Incorporated · Health Care · ref. ETF XLV · price $116.93
In short — 1 insider bought Corcept Therapeutics Incorporated over ~6 months (1 buy, total $3.3M, latest Mar 17, 26). Public Form 4 data, informative (not a performance signal).
Are Corcept Therapeutics Incorporated's executives buying their own shares? Here are the disclosed insider buys over the last 6 months — a transparency data point, not an outperformance signal.
📈 1-year price
$116.93+68.1% over range
Aug 28, 25low $32.15 · high $123.57Aug 27, 26
📏 Click 2 points (left → right) to measure the change · click again to clear.
SellBuy
Buy
80% recommend buying · 5 analysts
Latest insider buys on Corcept Therapeutics Incorporated
| Date | Insider | Role | Shares | Amount |
|---|---|---|---|---|
| Mar 17, 26 | Baker G Leonard Jr | Dir | 100,000 | $3.3M |
⚠️ Open-market buys reported to the SEC (Form 4). Transparency data, not advice nor an outperformance signal (our backtests show no reliable edge).
Frequently asked questions
Have Corcept Therapeutics Incorporated's executives bought shares recently?
1 Corcept Therapeutics Incorporated insider(s) bought $3.3M over ~6 months (latest Mar 17, 26). A buy shows confidence, but our backtests show no performance edge.
Is insider buying a good signal for CORT?
It's useful transparency data, but NOT a performance guarantee: our historical tests show no reliable edge from following insider buys. Cross-check with fundamentals and analyst views.
Where does this data come from?
From Form 4 filings with the SEC (mandatory for officers and 10%+ holders), aggregated and refreshed regularly.
💬 A question about Corcept Therapeutics Incorporated? The JPI assistant answers using our backtest data.
Keep exploring Corcept Therapeutics Incorporated